Stockscreener 앱 받기
148.95
3.60%
5.18
시간 외 거래:
148.74
-0.21
-0.14%
전일 마감가:
$143.77
열려 있는:
$143.555
하루 거래량:
11.10M
Relative Volume:
1.53
시가총액:
$184.91B
수익:
$29.45B
순이익/손실:
$8.51B
주가수익비율:
21.96
EPS:
6.7823
순현금흐름:
$9.46B
1주 성능:
-1.62%
1개월 성능:
+5.66%
6개월 성능:
+30.75%
1년 성능:
+33.00%
1일 변동 폭
$143.37
$150.00
1주일 범위
$143.09
$152.46
52주 변동 폭
$93.37
$157.29
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
148.95 | 178.48B | 29.45B | 8.51B | 9.46B | 6.7823 |
|
LLY
Lilly Eli Co
|
1,051.99 | 964.13B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
248.43 | 586.74B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
232.08 | 397.29B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
208.45 | 316.32B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
168.62 | 315.82B | 54.72B | 14.02B | 15.32B | 7.1855 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-11 | 재확인 | Needham | Buy |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Gilead Sciences, Inc. $GILD Shares Sold by APG Asset Management N.V. - MarketBeat
Assessing Gilead Sciences (GILD) Valuation As Recent Share Price Momentum Meets Conflicting Fair Value Signals - Yahoo Finance
Gilead Sciences, Inc. $GILD Holdings Cut by Rafferty Asset Management LLC - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by DNB Asset Management AS - MarketBeat
Argent Trust Co Buys 21,785 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Josh Gottheimer makes key trades in Gilead Sciences and Intercontinental Exchange By Investing.com - Investing.com South Africa
P/E Ratio Insights for Gilead Sciences - Benzinga
Gilead Sciences Inc Stock Moved Up by 3.72% on Feb 27: What Investors Need To Know - TradingKey
Rx Rundown: Gilead Sciences, Viatris, Generate Biomedicines and moreMM+MMedical Marketing and Media - Medical Marketing and Media
Gilead Sciences Stock: Is GILD Outperforming the Healthcare Sector? - Barchart.com
Handelsbanken Fonder AB Lowers Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Q3 EPS Estimates for Gilead Sciences Cut by Zacks Research - MarketBeat
MAI Capital Management Purchases 13,649 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Erste Asset Management GmbH Sells 30,299 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Clifford Swan Investment Counsel LLC Trims Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Foundation Grants County College of Morris Foundation $150,000 Towards New Center for Health Professions Building - TAPinto
PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race - GlobeNewswire Inc.
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $161.00 - MarketBeat
Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data - BioSpace
Mitsubishi UFJ Asset Management Co. Ltd. Has $287.48 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Intech Investment Management LLC Raises Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Q1 EPS Forecast Lifted by Zacks Research - MarketBeat
Fox Run Management L.L.C. Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead’s Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy - BioSpace
Gilead Sciences (GILD) HIV Pill Shows Promising Results in Phase 3 Trials - GuruFocus
Gilead reports positive phase 3 data for HIV treatment combo - Investing.com
Gilead's BIC/LEN Pill Maintains Viral Suppression in HIV Trials - Intellectia AI
Gilead (GILD) Introduces Promising HIV Treatment in Phase 3 Tria - GuruFocus
Gilead's experimental HIV treatment shows low discontinuation rates in studies - Reuters
Gilead's New HIV Treatment Shows Promise in Phase 3 Trials - Intellectia AI
Gilead HIV drug combination maintains viral suppression in phase 3 trials - StreetInsider
Gilead paints clearer picture of next-gen HIV tablet's prowess with results from 2 late-stage studies - Fierce Pharma
Merck’s New HIV Drug Matches Gilead’s Biktarvy in Phase 3 Trials as Keytruda Patent Cliff Nears - Barron's
Arcellx set to report earnings amid pending Gilead acquisition - Investing.com
Daiwa Securities Adjusts Price Target on Gilead Sciences to $161 From $129, Maintains Outperform Rating - marketscreener.com
UBS reiterates Buy on Gilead stock after Aclx acquisition - Investing.com
UBS reiterates Buy on Gilead stock after Aclx acquisition By Investing.com - Investing.com UK
Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy - Benzinga
Analyst recommendations: IBM, Axon, Caterpillar, Fair Isaac, Gilead… - marketscreener.com
Decoding Gilead Sciences Inc (GILD): A Strategic SWOT Insight - GuruFocus
Gilead to Acquire Arcellx for Up to $7.8 Billion, Doubling Down on Next-Generation CAR-T Therapy - NAI500
GILEAD SCIENCES, INC. SEC 10-K Report - TradingView
Arcellx Stock Explodes 77% After Gilead’s $7.8 Billion Takeover Announcement. Here’s What Investors Should Know - TIKR.com
Gilead Sciences acquires biotech company Arcellx for $7.8 billion - AKM.RU
GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel - TradingView
Gilead’s Arcellx Deal Deepens Oncology Focus And Raises Valuation Questions - simplywall.st
Gilead to acquire Rockville-area cancer drug developer Arcellx in $8B deal - Technical.ly
Arcellx stock steadies near $115 after Gilead’s $7.8 billion takeover bid — what traders watch next - TechStock²
Gilead Sciences Acquiring Arcellx to Consolidate Anito-Cel Ownership, UBS Securities Says - marketscreener.com
Gilead-Genhouse's $1.5B+ deal boosts synthetic lethality push - BioWorld MedTech
Truist reiterates Gilead Sciences stock rating on Arcellx deal - Investing.com UK
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
길리어드 사이언스 주식 (GILD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Feb 17 '26 |
Option Exercise |
66.64 |
25,000 |
1,666,000 |
148,288 |
| Mercier Johanna | Chief Comm & Corp Aff Officer |
Feb 17 '26 |
Sale |
154.44 |
28,000 |
4,324,228 |
120,288 |
| Dickinson Andrew D | Chief Financial Officer |
Feb 17 '26 |
Sale |
154.43 |
3,000 |
463,290 |
167,779 |
0.45%
2.33%
자본화:
|
볼륨(24시간):